long intergenic non-protein coding RNA 644Genealiases: []
Q-omics provides the consensus-scored LINC00644 profile across patient tissues and cancer cell-line models. LINC00644 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LINC00644 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, LINC00644 RNA expression shows 6,014 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight KICH, BRCA, and PAAD as cancer lineages where LINC00644 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00644 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00644 survival associations across molecular data types. LINC00644 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00644 RNA expression–survival associations across cancer types. High LINC00644 expression shows unfavorable associations in KICH, HNSC, COAD, THCA and BLCA, but favorable associations in GBM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for LINC00644 RNA expression.
This table summarizes LINC00644 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00644. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00644 shows lower tumor expression in BRCA, PRAD and LUSC. The BRCA box plot shows higher LINC00644 RNA expression in normal versus tumor tissue (log2 FC = −0.074, t-test p < 0.001).
This table shows molecular features associated with LINC00644 in patient tissues and cancer cell lines. In patient samples, LINC00644 shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set.
